Fig. 4From: Neurological management and work-up of neurotoxicity associated with CAR T cell therapyIL-6 levels and MoCA scores of two exemplary ICANS patients compared with all patients that neither had ICANS nor CRS Day 0: day of CAR T cell therapy. Patients 7 and 11 developed immune effector cell-associated neurotoxicity syndrome (ICANS) grade 2. MoCA: Montreal Cognitive AssessmentBack to article page